Apollo Endosurgery Prices $31 Million Public Offering

Apollo Endosurgery Announces Pricing Of $31 Million Public Offering

AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (NASDAQ: APEN), a medical technology company primarily focused on the design, development and commercialization of innovative medical devices that can be used for the treatment of obesity, today announced the pricing of an underwritten public offering of 5,689,090 shares of its common stock at a public offering price of $5.50 per share, before underwriting discounts and commissions. All of the common stock is being offered by Apollo. In addition, Apollo has also granted the underwriters a 45-day option to purchase up to an additional 853,363 shares of common stock. The offering is expected to close on July 25, 2017, subject to customary closing conditions.

Craig-Hallum Capital Group LLC and Roth Capital Partners are acting as joint book-running managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on July 19, 2017. The offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus related to the offering has been filed with the SEC and is available on the SEC's website, located at www.sec.gov. When available, copies of the final prospectus relating to the offering may be obtained from Craig-Hallum Capital Group LLC at 222 South Ninth Street, Suite 350, Minneapolis, Minnesota 55402, Attention: Equity Capital Markets, by telephone at 612-334-6300, or by e-mail at prospectus@chlm.com, or alternatively from Roth Capital Partners, LLC, Attention: Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, by telephone at 800-678-9147, or by email at rothecm@roth.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 80 countries today.